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Background: Inflammation processes are important participants in the pathophysiology of hypertension and
cardiovascular diseases. The role of the alpha7 nicotinic acetylcholine receptor (α7nAChR) in inflammation has
recently been identified. Our previous study has demonstrated that the α7nAChR-mediated cholinergic
anti-inflammatory pathway is impaired systemically in the genetic model of hypertension. In this work, we
investigated the changes of α7nAChR expression in a model of secondary hypertension.
Methods: The 2-kidney 1-clip (2K1C) hypertensive rat model was used. Blood pressure, vagus nerve function, serum
tumor necrosis factor-α (TNF-α) and both the mRNA and protein levels of α7nAChR in tissues from heart, kidney
and aorta were measured at 4, 8 and 20 weeks after surgery.
Results: Compared with age-matched control, it was found that vagus nerve function was significantly decreased
in 2K1C rats with the development of hypertension. Serum levels of TNF-α were greater in 2K1C rats than in
age-matched control at 4, 8 and 20 weeks. α7nAChR mRNA in the heart was not altered in 2K1C rats. In the kidney
of 2K1C rats, α7nAChR expression was significantly decreased at 8 and 20 weeks, but markedly increased at
4 weeks. α7nAChR mRNA was less in aorta of 2K1C rats than in age-matched control at 4, 8 and 20 weeks. These
findings were confirmed at the protein levels of α7nAChR.
Conclusions: Our results suggested that secondary hypertension may induce α7nAChR downregulation, and the
decreased expression of α7nAChR may contribute to inflammation in 2K1C hypertension.
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Secondary hypertension affects a small but significant
number of the hypertensive population. It is estimated
that approximately 15% of hypertensive patients have
identifiable conditions causing the blood pressure eleva-
tion [1,2]. Renovascular hypertension represents the
most common cause of potentially curable secondary
hypertension [3]. Therefore, a better understanding of
the mechanisms in the end-organ damage could provide
new avenues for prevention of cardiovascular events.
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reproduction in any medium, provided the orexperimental model that in many respects resembles
human renovascular hypertension [4].
Inappropriately activated systemic and local tissue
renin-angiotensin systems (RAS) contribute to the
hemodynamic and metabolic abnormalities that lead to
hypertension. Furthermore, the system can contribute to
end-organ damage, at least partly by promoting inflamma-
tion [5-7]. Recent evidences indicate that neuronal cholin-
ergic systems can modulate inflammatory responses by
controlling the release of proinflammatory cytokines [8,9],
and that nonneuronal acetylcholine (ACh) synthesis and
release machinery are downregulated in inflammation
[10]. The anti-inflammatory actions mediated by either
neuronal or nonneuronal cholinergic system are believed
to depend on activation of alpha7 nicotinic acetylcholine
receptor (α7nAChR) [11-13], and α7nAChR is therefore
proposed as an essential regulator of inflammation and a
promising pharmacological strategy against infectious andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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linergic pathways contribute to the development of end-
organ damage during hypertension, then downregulation
of the α7nAChR seems likely.
Our previous study [12] has demonstrated that
α7nAChR-mediated signaling is impaired systemically in
spontaneously hypertensive rats (SHR, a well-known
genetic model of hypertension), which contributes to
end-organ damage. Downregulation of α7nAChR occurs
at the age of 20 and 40 weeks, but not 4 weeks. Therefore
it seems possible that elevated blood pressure may be the
fundamental cause responsible for α7nAChR downregu-
lation regardless of the genetic factors. In the present
study, using 2K1C hypertensive rats, we test the hypoth-
esis that hypertension induces vagus nerve dysfunction
and downregulation of α7nAChR in secondary hyperten-
sion, which contribute to inflammation in hypertension.
Methods
Animals
Male Sprague–Dawley (SD) rats (8 weeks of age; Sino-
British SIPPR/BK Lad Animal Ltd, Shanghai, China)
were housed in a 12/12-hour light/dark cycle with free
access to food and water. All the animals used in this
work received humane care in compliance with the insti-
tutional animal care guidelines and the Guide for Care
and Use of Laboratory Animals published by the Na-
tional Institutes of Health.
Preparation of 2K1C
Male SD rats weighing 160 to 180 g were anesthetized
with a combination of ketamine (40 mg/kg) and diaze-
pam (6 mg/kg). The right renal artery was isolated
through a flank incision, and a silver clip (0.2 mm in-
ternal gap) was placed on the renal artery, as described
previously [15]. Sham-operated rats that underwent the
same surgical procedure except for placement of the
renal artery clip served as controls.
Blood pressure and heart rate measurement
Systolic blood pressure (SBP), diastolic blood pressure
(DBP), and heart rate (HR) were continuously recorded
in conscious rats as described previously [12]. Briefly,
rats were anesthetized with a combination of ketamine
(40 mg/kg, i.p.) and diazepam (6 mg/kg, i.p.). A catheter
was inserted into the lower abdominal aorta via the
femoral artery for blood pressure (BP) measurement.
Another catheter was placed into the abdominal vena
cava via the femoral vein for drug administration. The
catheters were filled with heparinized saline (150 IU/ml)
to prevent clotting and were plugged with paraffin-filled
23-guage hypodermic needles. After a 2-day recovery
period, rats were placed in a Plexiglas cage (30 cm
diameter). The aortic catheter was connected to a BPtransducer via a rotating swivel, which allowed the ani-
mal to move freely. Signals from the transducer were
recorded by a computerized system (MPA 2000 M,
Alcott Biotech Co LTD, Shanghai, China). SBP, DBP
and HR were averaged beat-to-beat during the 5 min
test period before and after atropine injection (0.03 mg/
kg, i.v.), atropine induced HR changes were used to as-
sess cardiac vagal tone.
Determination of tumor necrosis factor-α (TNF-α) levels
by ELISA
Male rats were anesthetized with a combination of keta-
mine (40 mg/kg, i.p.) and diazepam (6 mg/kg, i.p.).
Blood samples were collected. Blood was centrifuged at
3,000 g for 15 min at 4°C to collect serum. The serum
was kept at −80°C until analyzed. The levels of TNF-α
were measured with commercial ELISA kits (R&D Sys-
tems, Minneapolis, MN, USA).
RNA extraction and real-time quantitative PCR analysis
Total RNA was extracted from rat tissues using TRIzol re-
agent (Invitrogen) according to the instructions of the
manufacturer. First-strand cDNA was amplified by PCR
using specific primers for the cDNA of α7nAChR (acces-
sion no. NM_012832.3), 5' GGTCGTATGTGGCCGTT
TG 3' (sense) and 5' TGCGGTTGGCGATGTAGCG 3'
(antisense) and GAPDH as an internal control (accession
no. NM_017008.3), 5' AGACCTCTATGCCAACACAG
TGC 3' (sense) and 5' GAGCCACCAA TCCACACA-
GAGT 3' (antisense). Real-time quantitative PCR was per-
formed using the Chromo4™ real-time PCR detection
system (Bio-Rad) and the SYBR Premix Ex Taq Mixture
(Takara) with specific primers. The PCR reactions were
initiated with denaturation at 95°C for 10 s, followed by
amplification with 40 cycles at 95°C for 10 s, and anneal-
ing at 60°C for 20 s (two-step method). Finally, melting
curve analysis was performed from 60°C to 85°C. Data
were evaluated with Opticon Monitor™ version 3.0 soft-
ware. All samples were performed in triplicate. The rela-
tive expression of the target gene was normalized to the
level of GAPDH in the same cDNA.
Protein extraction and western blot analysis
Tissues were washed in ice-cold phosphate-buffered sa-
line (PBS) and homogenized in a Tris–HCl buffer
(20 mmol/L, pH 7.5) containing EDTA (2 mmol/L), NP-
40 (1%w/v), Triton-100 (1%w/v), PMSF (2 mmol/L),
leupeptin (50 μg/ml), aprotinin (25 μg/ml), pesptatin A
(10 μg/ml) and dithiothreitol (DTT2 mmol/L). The
supernatant was obtained by centrifugation at 11,000 g
for 15 min at 4°C. The protein concentration was deter-
mined using a BCA Protein Assay Kit (Beyotime,
China). Samples of approximately 30 μg were run on
10% SDS-PAGE. The proteins were electro-transferred
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PVDF membranes were incubated with primary anti-
body (anti-α7nAChR, Sigma-Aldrich, 1:5,000) for 2
hours at 25°C and then incubated with horseradish per-
oxidase (HRP) conjugated secondary antibodies (1:1,000
dilution; Bethyl Laboratories, Inc., Montgomery, TX).
The bound antibody was visualized on a Kodak Biomax
film (Eastman Kodak, Rochester, NY) using a Super-
signal substrate chemiluminescence detection kit
(Pierce, Rockford, IL). The relative expression of the tar-
get protein was normalized to the level of GAPDH in
the same sample [12].
Statistical analysis
All values are expressed as means ± SEM. Results were
analyzed by paired (within-group) or unpaired (between
2 groups) Student t test or ANOVA, followed by Tukey
test (among 3 or more groups). Two-sided P< 0.05 was
considered statistically significant.
Results
Basal arterial pressure and heart rate in 2K1C rats
Both SBP and DBP were significantly increased at 4, 8
and 20 weeks after 2K1C surgery when compared with
age-matched sham-operated rats. The SBP reached a
distinction about 50 mmHg at 4 and 8 weeks, and
approached to 70 mmHg at 20 weeks. For DBP, the gap
was less than 25 mmHg at 4 weeks and around
35 mmHg at 8 and 20 weeks. HR was not changed at 4,
8 and 20 weeks between the 2K1C and control rats
(Table 1).
Vagal tone in 2K1C rats
To assess the vagal tone, the cardiovascular effects of at-
ropine were compared between 2K1C and sham-
operated rats. Atropine 0.03 mg/kg (i.v.) did not affect
both SBP and DBP (Table 1). However, atropine-inducedTable 1 Blood pressure and heart rate changes induced by at
2K1C rats (n =6)
Sham
Pre-atropine Post
4 weeks SBP (mmHg) 107± 2.1 108±
DBP(mmHg) 78± 3.8 82±
HR (beat/min) 342± 8.6 405±
8 weeks SBP (mmHg) 105± 1.3 109±
DBP(mmHg) 70± 1.9 73±
HR (beat/min) 332± 4.4 395±
20 weeks SBP (mmHg) 106± 1.1 108±
DBP(mmHg) 72± 1.0 72±
HR (beat/min) 335± 6.8 388±
Values are expressed as mean ± SEM. *P< 0.05 vs aged-matched sham-operated ra
systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; 2K1C, two-kidntachycardia was significantly less in 2K1C hypertensive
rats than sham-operated rats at 4 weeks (42 ± 6.6 vs.
63 ± 2.8 beat/min; n = 6, P< 0.05), 8 weeks (33 ± 5.4 vs.
62 ± 5.0 beat/min; n = 6, P< 0.01), and 20 weeks (32 ± 5.1
vs. 54 ± 6.2 beat/min; n = 6, P< 0.01), indicating a deficit
in cardiac vagal tone in 2K1C hypertensive rats
(Figure 1).
Inflammation induced by hypertension in 2K1C rats
To investigate the levels of proinflammatory cytokine in
2K1C rats, level of TNF-α in serum was measured.
Serum TNF-α in 2K1C rats was significantly greater than
age-matched sham-operated ones at 4 weeks (43 ± 3.5 vs.
14 ± 2.5 pg/ml; n = 7, P< 0.05), 8 weeks (57 ± 2.7 vs.
19 ± 1.5 pg/ml; n = 7, P< 0.05) and 20 weeks (43 ± 2.8
vs. 18 ± 2.0 pg/ml; n = 7, P< 0.05) (Figure 2).Expression of α7nAChR mRNA and its encoded protein in
aorta, kidney and heart of 2K1C rats
Expression of α7nAChR mRNA and its encoded protein
were determined to assess the function of cholinergic
pathway in 2K1C rats.
Aorta
Real-time PCR was undertaken to measure the level of
mRNA. It was found that α7nAChR mRNA in aorta was
significantly less in 2K1C group than in control group at
4 weeks, 8 weeks, and 20 weeks (Figure 3A). Then we
investigated whether this difference was translated at the
protein level. The results from Western Blot displayed
that α7nAChR in aorta was markedly reduced in 2K1C
hypertensive rats when compared to the sham-operated
ones at 4 weeks (0.52 ± 0.05 vs. 1.00 ± 0.15; n = 5, P< 0.05),
8 weeks (0.55 ± 0.05 vs. 1.00 ± 0.07; n = 5, P< 0.05), and
20 weeks (0.64 ± 0.04 vs. 1.00 ± 0.16; n = 5, P< 0.05)
(Figure 3B).ropine (i.v., 0.03 mg/kg) between sham-operated and
2K1C
-atropine Pre-atropine Post-atropine
2.2 161± 8.5 * 163± 7.8
3.7 102± 3.7 * 105± 3.1
6.8 ## 380± 16.4 422± 15.6 #
1.6 155± 4.3 * 156± 5.5
1.3 105± 6.2 * 107± 6.8
5.6 ## 336± 9.3 369± 9.3 #
1.1 174± 4.2 * 176± 2.8
1.3 109± 2.8 * 110± 2.0
8.9 ## 345± 6.2 377± 8.8 #
ts (unpaired t test). #P< 0.05, ##P< 0.01 vs Pre-atropine (paired t test). SBP,
ey one-clip.
Figure 3 Expression of α7nAChR on mRNA (A) and protein (B)
levels in aorta of 2K1C hypertensive rats at 4 weeks, 8 weeks,
and 20 weeks after surgery. The GAPDH was used as an internal
Figure 1 Effects of atropine (i.v., 0.03 mg/kg) on heart rate in
sham-operated rats and 2K1C hypertensive rats (n = 6). ΔHR,
the difference of heart rate between pre-atropine and post-atropine
injection. Atropine induced HR increase in sham-operated rats was
significantly larger than in 2K1C group. *P< 0.05, **P< 0.01 vs
age-matched sham-operated group (unpaired t test).
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Expression of α7nAChR mRNA in the kidney of 2K1C
rats showed a temporary but significant increase at
4 weeks when compared to the control ones. However,
α7nAChR mRNA in the kidney of 2K1C was less than in
control group at 8 weeks and 20 weeks (Figure 4A).
These results from real-time PCR were confirmed at
protein levels (Figure 4B).
Heart
Dissimilar to results from aorta and kidney, expression
of α7nAChR mRNA and its encoded protein in the tis-
sues from the left ventricles were unchanged between
the two groups at 4, 8 and 20 weeks (Figure 5).Figure 2 Serum levels of TNF-α after surgery to induce 2K1C
hypertension at 4, 8 and 20 weeks. *P< 0.05 compared with
aged-matched sham-operated group. Data are means ± SEM
(n = 7 in each group) (unpaired t test).
control. Data represent mean ± SEM (n = 7 in each group for
real-time quantitative PCR analysis and n= 5 in each group for
Western Blot analysis). *P< 0.05 vs aged-matched sham-operated
group (unpaired t test).Discussion
In this work, we assessed the changes of cholinergic
pathway with a model of secondary hypertension
induced by 2K1C through determination of vagus nerve
function and α7nAChR expression. We found that vagus
nerve function was decreased after 2K1C surgery (i.e. at
4, 8 and 20 weeks of age); expression of α7nAChR was
downregulated in aorta (from 4 weeks) and kidney (from
8 weeks), and serum TNF-α was increased in 2K1C
hypertension.
A growing amount of evidences suggest that inflam-
mation participates in the pathogenesis of hypertension
[16,17], and hypertension may be in part an inflamma-
tory disease because C-reactive protein level, a marker
of systemic inflammation, is associated with future
Figure 4 Expression of α7nAChR on mRNA (A) and protein (B)
levels in kidney of 2K1C hypertensive rats at 4 weeks, 8 weeks,
and 20 weeks after surgery. The GAPDH was used as an internal
control. Data represent mean ± SEM (n = 7 in each group for
real-time quantitative PCR analysis and n= 5 in each group for
Western Blot analysis). *P< 0.05 vs aged-matched sham-operated
group (unpaired t test).
Figure 5 Expression of α7nAChR on mRNA (A) and protein (B)
levels in heart of 2K1C hypertensive rats at 4 weeks, 8 weeks,
and 20 weeks after surgery. The GAPDH was used as an internal
control. Data represent mean ± SEM (n = 7 in each group for
real-time quantitative PCR analysis and n= 5 in each group for
Western Blot analysis). *P< 0.05 vs aged-matched sham-operated
group (unpaired t test).
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unclear how hypertension is related to the inflammatory
process, and what are the causes of inflammation.
It is demonstrated that hypertensive patients are char-
acterized by a sympathovagal imbalance with a reduction
of vagal tone [19,20]. Vagal function is impaired in
human hypertension, which is associated with an
increased risk for morbidity and mortality and may pre-
cede the development of risk factors [21]. The neuron
cholinergic anti-inflammatory pathway suggests that
vagus nerve can modulate the innate immune response
and prevent inflammation through activation of
α7nAChR in macrophages by releasing ACh, and stimu-
lation of vagus nerve attenuates systemic inflammatoryresponse, including inhibition of proinflammatory cyto-
kines release, such as TNF-α and interleukin-1β
[8,11,22]. Therefore, it seems reasonable that chronic
hypertension results in decreased vagal function, and
decreased vagal function may contribute to inflamma-
tion in hypertension. In this work, we determined the
tachycardic response to atropine, a classic index of car-
diac vagal tone, which reflects vagal function [23]. In
accord with previous study indicating depressed cardiac
vagal responsiveness in renovascular hypertensive rats
Chen et al. BMC Cardiovascular Disorders 2012, 12:38 Page 6 of 7
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decreased in 2K1C hypertensive rats. These results sug-
gested that vagus nerve might be a link between hyper-
tension and inflammation.
It is well accepted that the α7nAChR, expressed in pri-
mary immune cells, is a pivotal mediator of the choliner-
gic anti-inflammatory pathway [8,9,11]. Direct activation
of α7nAChR exerts a protective anti-inflammatory
effects during renal ischemia/reperfusion injury [25], and
regulates cytokines production in sepsis [26]. Our previ-
ous study found that chronic treatment of SHR with the
α7nAChR agonist PNU-282987 relieved end-organ dam-
age and inhibited tissue levels of pro-inflammatory cyto-
kines [12]. Vida et al. suggested that cholinergic agonists
inhibited systemic inflammation via the α7nAChR, and
α7nAChR was a molecular link between the parasympa-
thetic and sympathetic system to control inflammation
[27]. In this study, we compared the expression of
α7nAChR in the tissues from aorta, kidney and left ven-
tricle between 2K1C hypertensive rats and control ones,
and found that expression of α7nAChR was downregu-
lated in aorta (from 4 week) and kidney (from 8 weeks).
We also measured serum TNF-α, and found that levels
of TNF-α in 2K1C hypertensive rats were greater than
control at 4, 8 and 20 weeks. Thus decreased vagal func-
tion might play a role on the downregulation of
α7nAChR, which might be responsible for the increased
inflammatory cytokines in 2K1C hypertensive rats.
A main object of this study was to characterize the ex-
pression of α7nAChR in tissues from the aorta, kidney
and heart in secondary hypertension induced by 2K1C.
It was demonstrated that BP begins to increase 7 days
after 2K1C surgery and reaches a level of 160 mmHg for
SBP around 4 weeks [28-30], whereas the development
of increased BP in SHR occurs largely between the ages
of 4 and 12 weeks [31], and the relatively stable hyper-
tensive levels are reached by about 16–20 weeks of age
[32]. The results that α7nAChR downregulation in aorta
occurred at 4 weeks in 2K1C rats and at 20 weeks in
SHR suggested that BP was possibly the fundamental
cause for changes of α7nAChR expression in aorta.
The RAS can contribute to end-organ damage, such as
vascular remodeling, and renal fibrosis and dysfunction,
at least partly by promoting inflammation [33]. It has
been shown that the increased circulating Angiotensin II
(ANG II) plays an important role in the development of
2K1C hypertension, and the augmentation of intrarenal
ANG II levels plays the crucial role in the maintenance
phase of 2K1C hypertension [34]. Hiyoshi et al. found
that plasma renin concentrations was elevated in mice
within 14 days after 2K1C surgery, followed by reduction
to sham levels at 42 days. While the angiotensin II sub-
type 2 (AT2) receptor mRNA levels revealed a 2-fold in-
crease in the thoracic aortas on day 14, and thenreturned to sham levels by day 42 in these mice [35].
Similar to changes of AT2 receptor occurred in 2K1C
mice, we postulate that the upregulation of α7nAChR in
the kidney at 4 weeks in our study might be a protective
response to inflammation induced by Angiotensin II.
Different from SHR, the expression of α7nAChR in heart
of 2K1C rats was unchanged within 20 weeks, although
BP remained at high levels. Further studies are needed
to explore this issue.
Our results, expression of α7nAChR was downregu-
lated in aorta (from 4 weeks) and kidney (from 8 weeks),
but unchanged in heart, also suggested that the aorta
may be a sensitive organ to suffer from hypertension-
induced α7nAChR downregulation. Interestingly,
Grundy et al. [18] proposed that inflammatory markers,
such as high sensitive C-reactive protein in hypertension,
were possibly a response to products from arterial in-
flammation, and hypertension at least in part was a
product of arterial pathology. Though the cause of arter-
ial inflammation is unknown, downregulated α7nAChR
in the aorta during hypertension may play a role.
Conclusion
In conclusion, downregulation of the α7nAChR occurred
with the development of hypertension induced by 2K1C.
Decreased expression of α7nAChR may contribute to in-
flammation in secondary hypertension.
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